Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, van der Zee HH, Wozniak MB, Martinez AL, Kasparek T, Bachhuber T, Ortmann CE, Lobach I, Thomas N, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: lobach i. J Eur Acad Dermatol Venereol. 2024 Oct 19. doi: 10.1111/jdv.20369. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39425517
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Quattrone A, Franzmeier N, Huppertz HJ, Klietz M, Roemer SN, Boxer AL, Levin J, Höglinger GU; AL‐108‐231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE‐PSP Group. Quattrone A, et al. Mov Disord. 2024 Aug;39(8):1329-1342. doi: 10.1002/mds.29866. Epub 2024 Jun 2. Mov Disord. 2024. PMID: 38825840
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: lobach i. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: lobach i. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499. doi: 10.1111/jdv.19681. Epub 2023 Dec 6. J Eur Acad Dermatol Venereol. 2024. PMID: 38058224 Clinical Trial. No abstract available.
Experimental demonstration of optical stochastic cooling.
Jarvis J, Lebedev V, Romanov A, Broemmelsiek D, Carlson K, Chattopadhyay S, Dick A, Edstrom D, Lobach I, Nagaitsev S, Piekarz H, Piot P, Ruan J, Santucci J, Stancari G, Valishev A. Jarvis J, et al. Among authors: lobach i. Nature. 2022 Aug;608(7922):287-292. doi: 10.1038/s41586-022-04969-7. Epub 2022 Aug 10. Nature. 2022. PMID: 35948709 Free PMC article.
110 results